ICAM1 and metabolic dysfunction-associated steatohepatitis: In addition, treatment with CU06-1004 only led to significantly lower mRNA expression of E-selectin, ICAM-1, VCAM-1 and CD31 in mice with mild NASH, relative to the CD groups (Fig 5E–5H).